Affordable Access

deepdyve-link
Publisher Website

Influence of a Novel Food-Grade Formulation of Red Chili Extract (Capsicum annum) on Overweight Subjects: Randomized, Double-Blinded, Placebo-Controlled Study.

Authors
  • Joseph MSc, Ashil1
  • John PhD, Febi1
  • Thomas MSc, Jestin V2
  • Sivadasan, Syam Das PhD1
  • Maliakel PhD, Balu1
  • Mohan PhD, Ratheesh3
  • I M, Krishnakumar1
  • 1 Akay Natural Ingredients Pvt. Ltd., Cochin, Kerala, India. , (India)
  • 2 Leads Clinical Research and Bio Services Pvt. Ltd., Bangalore, Karnataka, India. , (India)
  • 3 St. Thomas College, Kottayam, Kerala, India. , (India)
Type
Published Article
Journal
Journal of dietary supplements
Publication Date
Jan 01, 2021
Volume
18
Issue
4
Pages
387–405
Identifiers
DOI: 10.1080/19390211.2020.1780363
PMID: 32578488
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Capsaicinoids from pungent red chilies (Capsicum annum and Capsicum frutescens) have received significant attention as a natural supplement for the management of obesity. However, the consumption of chili extract at physiologically relevant dosage of capsaicinoids is a challenge owing to its pungency and gastrointestinal discomforts. The present study reports the systemic absorption, safety and influence of a novel, food-grade, and sustained-release formulation of capsaicinoids-rich red chili extract using fenugreek dietary fiber (Capsifen®). Twenty-four healthy overweight subjects were randomized into placebo (n = 12) and Capsifen (n = 12) groups and supplemented with 200 mg × 1/day of Capsifen (4 mg capsaicinoids/day) for 28 days. Influence of Capsifen on eating behavior and appetite was followed by Three-Factor Eating Questionnaire (TFEQ) and Council of Nutrition Appetite Questionnaire (CNAQ), respectively. Consumption of Capsifen did not reveal any adverse events or deviations in hematology and biochemical parameters related to safety. However, a significant decrease in body weight (2.1%), w/h ratio (4%) and body mass index (BMI) (2.2%) were observed among Capsifen group when compared to placebo. The TFEQ and appetite analysis revealed a significant improvement in uncontrolled eating and reduction in appetite among Capsifen subjects. The UPLC-ESI-MS/MS analysis confirmed the absorption of capsaicinoids from CAP supplementation. The study further demonstrated the safety and tolerability of Capsifen at the investigational dosage. Thus, the significant reduction in anthropometric parameters such as body weight, w/h ratio, and BMI along with the improvement in eating behaviour as well as appetite, indicated the potential body weight management effect of Capsifen.

Report this publication

Statistics

Seen <100 times